S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.06
C$0.06
C$0.05
C$0.17
C$14.97M0.7838,143 shs15,000 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%+2.08%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-59.18%-99.22%
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00%0.00%-8.33%-21.43%-67.65%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.009 of 5 stars
0.00.00.00.00.63.30.0
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc. stock logo
BLU
BELLUS Health
2.00
HoldN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.26) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$12.82M-C$0.05N/AN/AN/AN/A-37.10%5/9/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A
0.11
0.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A

Insider Ownership

CompanyInsider Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
5.10%
Resverlogix Corp. stock logo
RVX
Resverlogix
43.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Resverlogix Corp. stock logo
RVX
Resverlogix
19272.17 millionN/ANot Optionable

NEPT, OXB, RVX, SPL, and BLU Headlines

SourceHeadline
Resverlogix Announces Change to Its Board of DirectorsResverlogix Announces Change to Its Board of Directors
finance.yahoo.com - February 21 at 8:02 PM
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalones Potential Therapeutic BenefitsResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
finance.yahoo.com - January 11 at 10:03 AM
Closing Bell: Resverlogix Corp flat on Tuesday (RVX)Closing Bell: Resverlogix Corp flat on Tuesday (RVX)
theglobeandmail.com - January 4 at 6:16 PM
Resverlogix Corp. (RVX) Earnings Dates & ReportsResverlogix Corp. (RVX) Earnings Dates & Reports
investing.com - December 19 at 7:28 PM
Resverlogix Corp RVXCFResverlogix Corp RVXCF
morningstar.com - November 18 at 5:49 PM
Resverlogix Corp RVXResverlogix Corp RVX
morningstar.com - November 1 at 11:18 AM
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
theglobeandmail.com - October 18 at 7:46 AM
Resverlogix Corp.: Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finanznachrichten.de - October 4 at 10:11 AM
Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finance.yahoo.com - October 4 at 10:11 AM
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
finance.yahoo.com - September 26 at 8:50 PM
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
finance.yahoo.com - August 29 at 10:13 AM
Closing Bell: Resverlogix Corp up on Wednesday (RVX)Closing Bell: Resverlogix Corp up on Wednesday (RVX)
theglobeandmail.com - August 24 at 3:35 PM
Closing Bell: Resverlogix Corp flat on Monday (RVX)Closing Bell: Resverlogix Corp flat on Monday (RVX)
theglobeandmail.com - August 14 at 10:02 PM
Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)
theglobeandmail.com - July 12 at 7:21 AM
Resverlogix Announces Warrant Repricing and One-Year ExtensionResverlogix Announces Warrant Repricing and One-Year Extension
finance.yahoo.com - June 29 at 11:09 PM
Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finanznachrichten.de - June 20 at 7:31 PM
Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finance.yahoo.com - June 20 at 7:31 PM
Resverlogix Announces New Insights into the Mechanism of Apabetalones Cardioprotective Benefit in Chronic Kidney Disease PatientsResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
finance.yahoo.com - June 12 at 6:42 PM
Canadian Investment Regulatory Organization Trading Halt - RVX.WT.ACanadian Investment Regulatory Organization Trading Halt - RVX.WT.A
finance.yahoo.com - June 7 at 1:32 PM
Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)
theglobeandmail.com - June 6 at 10:49 AM
Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)
theglobeandmail.com - May 25 at 12:52 AM
CBOE RUSSELL 2000 VOLATILITY IN (^RVX)CBOE RUSSELL 2000 VOLATILITY IN (^RVX)
finance.yahoo.com - May 18 at 12:38 AM
Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzzBromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz
news.google.com - May 13 at 3:47 PM
Resverlogix : MD&A Q1 2023 - Marketscreener.comResverlogix : MD&A Q1 2023 - Marketscreener.com
news.google.com - May 12 at 3:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BELLUS Health logo

BELLUS Health

NASDAQ:BLU
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Resverlogix logo

Resverlogix

TSE:RVX
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.